Teva’s CFO to Depart

From DCAT Value Chain Insights (VCI)

By People On The Move posted 05-01-2017 14:59


Teva Pharmaceutical Industries has confirmed that Eyal Desheh, group executive vice president, chief financial officer (CFO) will depart from Teva during the coming months following two earlier executive departures of the company’s chief executive officer (CEO) and president and CEO of the generics group. Teva will immediately begin a search to identify a successor to serve as CFO. Mr. Desheh will take part in the company’s upcoming first quarter earnings call on May 11, 2017.

Mr. Desheh became group executive vice president, CFO in 2008. From October 2013 to February 2014, Mr. Desheh served as acting president and CEO. Earlier in his career, from 1989 to 1996, he served as Teva’s deputy CFO.

Mr. Desheh’s departure follows the exit of Teva’s CEO, Erez Vigodman, in February 2017. Dr. Yitzhak Peterburg currently serves as interim president and CEO, while the company’s board searches for a new permanent CEO, who will have a significant role in identifying Mr. Desheh’s successor, according Dr. Sol Barer, chairman of Teva’s board of directors.

In addition to Mr. Vigodman’s and Mr. Desheh’s departures, Teva also saw the exit of its Global Generic Medicines Group’s president and CEO, Sigurdur Olafsson, who stepped down from his role and officially retired at the end of the first quarter. Mr. Olafsson was succeeded by Dipankar Bhattacharjee on December 5, 2016, who was appointed as president and CEO, Global Generic Medicines Group.

Source: Teva Pharmaceutical Industries


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription